D L Kelly

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. doi request reprint Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, School of Medicine, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 20:71-8. 2008
  2. pmc Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore School of Medicine, Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 38:543-51. 2012
  3. pmc Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Box 22147 Baltimore, MD 21228, United States
    Schizophr Res 103:161-8. 2008
  4. pmc Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    J Clin Psychopharmacol 31:86-91. 2011
  5. ncbi request reprint Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 15:181-6. 2003
  6. ncbi request reprint Atypical antipsychotic use in a state hospital inpatient adolescent population
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, USA
    J Child Adolesc Psychopharmacol 14:75-85. 2004
  7. ncbi request reprint Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD 21228, USA
    J Psychiatr Res 38:531-6. 2004
  8. ncbi request reprint Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine
    Deanna L Kelly
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    J Clin Psychiatry 66:80-4. 2005
  9. ncbi request reprint First-episode schizophrenia: a focus on pharmacological treatment and safety considerations
    Deanna L Kelly
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21228, USA
    Drugs 65:1113-38. 2005
  10. ncbi request reprint Reaching for wellness in schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Psychiatr Clin North Am 30:453-79. 2007

Detail Information

Publications61

  1. doi request reprint Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, School of Medicine, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 20:71-8. 2008
    ..This study examined weight and metabolic changes with two widely used antipsychotics, risperidone and olanzapine; addressing the issue of early monitoring for metabolic side effects...
  2. pmc Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore School of Medicine, Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 38:543-51. 2012
    ....
  3. pmc Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Box 22147 Baltimore, MD 21228, United States
    Schizophr Res 103:161-8. 2008
    ..53, df=1, p=0.019), for an effect size of 0.4. These results suggest that galantamine has no effect on cigarette smoking and that during galantamine treatment nicotine dependency scores worsen...
  4. pmc Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    J Clin Psychopharmacol 31:86-91. 2011
    ..The endocannabinoid system remains a promising target for pharmacotherapy of schizophrenia and obesity...
  5. ncbi request reprint Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 15:181-6. 2003
    ..High doses of olanzapine during 8 weeks of treatment did not increase lipids and liver enzymes like clozapine did. Olanzapine at 50 mg/day may be associated with more anticholinergic effects and weight gain than clozapine...
  6. ncbi request reprint Atypical antipsychotic use in a state hospital inpatient adolescent population
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, USA
    J Child Adolesc Psychopharmacol 14:75-85. 2004
    ..More research is needed to develop useful and specific practice guidelines in children and adolescents for these commonly used medications...
  7. ncbi request reprint Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD 21228, USA
    J Psychiatr Res 38:531-6. 2004
    ..Individuals who die by suicide experience higher rates of depressive symptoms, suicidal thoughts and positive symptoms during their life...
  8. ncbi request reprint Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine
    Deanna L Kelly
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    J Clin Psychiatry 66:80-4. 2005
    ..Furthermore, the need for thyroid function monitoring in patients taking this medication is not definitive...
  9. ncbi request reprint First-episode schizophrenia: a focus on pharmacological treatment and safety considerations
    Deanna L Kelly
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21228, USA
    Drugs 65:1113-38. 2005
    ....
  10. ncbi request reprint Reaching for wellness in schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Psychiatr Clin North Am 30:453-79. 2007
    ..Although treatment of risk factors for CHD is still far from ideal, all attempts should be made to strive for wellness to improve patients' long-term outcomes...
  11. ncbi request reprint Sexuality and schizophrenia: a review
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 30:767-79. 2004
    ..Treatment options and psychosocial issues pertaining to sexuality also are presented...
  12. ncbi request reprint Treatment considerations in women with schizophrenia
    Deanna L Kelly
    Department of Psychiatry, School of Medicine, Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    J Womens Health (Larchmt) 15:1132-40. 2006
    ..Additionally, it presents patient counseling issues in sexuality and health outcomes...
  13. pmc Clozapine underutilization and discontinuation in African Americans due to leucopenia
    Deanna L Kelly
    The Maryland Psychiatric Research Center, Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 33:1221-4. 2007
    ....
  14. ncbi request reprint Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Box 21247, Baltimore, MD 21228, USA
    Psychiatr Q 77:81-95. 2006
    ..The addition of divalproex was significantly more effective in reducing global symptoms (driven by hostility and anxiety) in the first month of adjunct treatment as compared to clozapine monotherapy and to previous clozapine treatment...
  15. pmc Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study
    D L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD, USA
    J Psychopharmacol 23:436-41. 2009
    ..Future studies should aim to relate remission criteria to functional outcomes, cognition, and other important symptom domains...
  16. ncbi request reprint Clozapine utilization and outcomes by race in a public mental health system: 1994-2000
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore 21228, USA
    J Clin Psychiatry 67:1404-11. 2006
    ..This study extends previous studies of clozapine by examining patient- and treatment-related factors that may help explain or eliminate reasons for differential prescribing...
  17. ncbi request reprint Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine
    D L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Psychiatr Serv 52:676-8. 2001
    ..These data suggest that among inpatients with schizophrenia or schizoaffective disorder, use of risperidone results in a higher discharge rate and a lower drug cost than use of olanzapine...
  18. pmc The impact of substance abuse on osteoporosis screening and risk of osteoporosis in women with psychotic disorders
    D L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, PO Box 21247, Baltimore, MD 21228, USA
    Osteoporos Int 22:1133-43. 2011
    ..Prevalence of osteoporosis was increased compared to controls in women with major mood disorders or women over 55 dually diagnosed with psychosis and substance use disorder...
  19. ncbi request reprint Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations
    D L Kelly
    University of Maryland School of Medicine, Maryland Psychiatric Research Center, Box 21247, Baltimore, MD 21228, USA
    Psychopharmacol Bull 35:66-79. 2001
    ..This paper will review the literature concerning real and theoretical implications of pharmacokinetic and pharmacodynamic interactions with ziprasidone, particularly with regard to these effects on the QTc interval...
  20. doi request reprint Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, P O Box 21247, Baltimore, MD 21228, USA
    Compr Psychiatry 51:298-302. 2010
    ....
  21. ncbi request reprint A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Box 21247, Baltimore, 21228, USA
    Psychoneuroendocrinology 31:340-6. 2006
    ..Overall, quetiapine was associated with a normalization of prolactin levels and had the greatest benefits among these drugs regarding sexual functioning...
  22. ncbi request reprint Clozapine treatment in patients with prior substance abuse
    Deanna L Kelly
    School of Medicine, University of Maryland, Baltimore, Maryland, USA
    Can J Psychiatry 48:111-4. 2003
    ..This study examined outcomes following discharge on clozapine for treatment-resistant schizophrenia patients with and without diagnosed substance abuse histories...
  23. pmc Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Box 21247, Baltimore, MD 21228, USA
    J Clin Psychiatry 71:304-11. 2010
    ..Cardiovascular disease (CVD) mortality in schizophrenia is more frequent than in the general population. Whether second-generation antipsychotics (SGAs) increase risk of CVD morbidity and mortality has yet to be determined...
  24. pmc Cigarette smoking and mortality risk in people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Schizophr Bull 37:832-8. 2011
    ..Greater smoking severity significantly increases this risk. Smoking cessation in people with schizophrenia deserves significant attention...
  25. ncbi request reprint A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    J Clin Psychiatry 70:518-25. 2009
    ..In animals, it has been shown to increase extracellular levels of acetylcholine and dopamine in cortical and hippocampal regions...
  26. pmc Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, United States
    Schizophr Res 107:134-8. 2009
    ....
  27. ncbi request reprint Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, Treatment Research Unit, University of Maryland, Baltimore 21228, USA
    Clin Neuropharmacol 28:163-8. 2005
    ..Treatment with first- and second-generation antipsychotics may demonstrate similar efficacy; however, patients treated with second-generation antipsychotics may be more likely to adhere to treatment...
  28. ncbi request reprint Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse
    R R Conley
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, School of Medicine 21228, USA
    Schizophr Res 33:95-101. 1998
    ..This suggests that olanzapine may be of benefit to SA patients who have a greater tendency for antipsychotic side effects and tardive dyskinesia...
  29. doi request reprint The effects of galantamine on psychopathology in chronic stable schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Clin Neuropharmacol 32:69-74. 2009
    ..This secondary analysis describes the effects of galantamine on psychopathology in people with schizophrenia...
  30. ncbi request reprint Plasma concentrations of high-dose olanzapine in a double-blind crossover study
    Deanna L Kelly
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Hum Psychopharmacol 21:393-8. 2006
    ..In conclusion, this study reports plasma olanzapine levels at high fixed doses of olanzapine (50 mg/day) in relation to side effects, symptoms, smoking, and gender...
  31. ncbi request reprint Management of treatment resistance in schizophrenia
    R R Conley
    Department of Psychiatry, University of Maryland School of Medicine, Baltimore 21228, USA
    Biol Psychiatry 50:898-911. 2001
    ....
  32. ncbi request reprint Cardiovascular disease in relation to weight in deceased persons with schizophrenia
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, 21228, USA
    Compr Psychiatry 46:460-7. 2005
    ....
  33. ncbi request reprint The effects of clozapine and high-dose olanzapine on brain function in treatment-resistant schizophrenia: a case study
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD 21228, USA
    J Psychopharmacol 18:429-31. 2004
    ..These findings suggest that high doses of olanzapine do not produce similar brain activation patterns as clozapine in people with treatment-resistant schizophrenia...
  34. pmc Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research
    Robert P McMahon
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland Baltimore Medical School, Baltimore, MD, USA
    Schizophr Bull 34:292-301. 2008
    ..Shortening placebo-controlled trials would reduce patient burden and ethical objections to prolonged administration of placebo and reduce potential bias due to high dropout rates in longer clinical trials...
  35. doi request reprint Comparison of clozapine response for inpatients in the research setting versus routine clinical practice
    Douglas L Boggs
    Maryland Psychiatric Research Center, School of Medicine, University of Maryland Baltimore, Baltimore, MD 21228, USA
    Psychiatr Q 79:111-9. 2008
    ..This study compares patient characteristics and treatment response between inpatients treated with clozapine in a research setting as compared to those initiated on clozapine during routine inpatient treatment...
  36. ncbi request reprint Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients
    Robert R Conley
    Maryland Psychiatric Research Center in the University of Maryland School of Medicine at Baltimore, MD 21228, USA
    Psychopharmacol Bull 40:77-97. 2007
    ..This review will assess the clinical relevance of these interactions for physicians and patients with schizophrenia...
  37. ncbi request reprint Comparison of clozapine use in Maryland and in Victoria, Australia
    Robert R Conley
    Maryland Psyciatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Psychiatr Serv 56:320-3. 2005
    ..This study examined the use of clozapine in Maryland and in Victoria, Australia...
  38. ncbi request reprint Rehospitalization risk with second-generation and depot antipsychotics
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland 21228, USA
    Ann Clin Psychiatry 15:23-31. 2003
    ..SGAs may provide better long-term prognoses and outcomes for patients with schizophrenia...
  39. ncbi request reprint Current status of antipsychotic treatment
    Robert R Conley
    University of Maryland, Maryland Psychiatric Research Center, Baltimore, MD 21228, USA
    Curr Drug Targets CNS Neurol Disord 1:123-8. 2002
    ..Optimization of treatment and understanding the exact mechanism of action of current antipsychotic medications will help pave the way for new drug targets in the future...
  40. ncbi request reprint Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone
    Matthew W Nelson
    VA Capitol Healthcare Network Mental Illness Research Education and Clinical Care Center MIRECC, Veterans Affairs, Maryland Health Care System, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Clin Neuropharmacol 26:297-8. 2003
    ..Controlled trials of quetiapine in the treatment of tardive dyskinesia should be pursued...
  41. ncbi request reprint Novel factor-based symptom scores in treatment resistant schizophrenia: implications for clinical trials
    Robert P McMahon
    Department of Psychiatry, Maryland Psychiatric Research Center, Spring Grove Hospital Grounds, Maple and Locust Avenues, PO Box 21247, Baltimore, MD 21228, USA
    Neuropsychopharmacology 26:537-45. 2002
    ..We recommend these four factor scores as clinical trial outcomes in patients with treatment resistant schizophrenia...
  42. pmc The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements
    Robert W Buchanan
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Bull 36:71-93. 2010
    ....
  43. ncbi request reprint Substitution of immediate-release valproic acid for divalproex sodium for adult psychiatric inpatients
    J D Sherr
    School of Pharmacy, University of Maryland, Baltimore, USA
    Psychiatr Serv 49:1355-7. 1998
    ..Costs were reduced 83 percent; annual savings per patient was approximately $905. These preliminary results suggest that many chronic psychiatric inpatients stabilized on divalproex may be safely switched to valproic acid...
  44. ncbi request reprint Circumstances of suicide among individuals with schizophrenia
    Julie A Kreyenbuhl
    Maryland Psychiatric Research Center, University of Maryland, PO Box 21247, Baltimore, MD 21228, USA
    Schizophr Res 58:253-61. 2002
    ..Suicide in schizophrenia is a significant clinical problem; thus, prior suicidal activity and depressive symptoms should be addressed because opportunities to intervene immediately before the act are limited...
  45. ncbi request reprint Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects
    Robert R Conley
    Maryland Psychiatric Research Center, University of Maryland, Baltimore, Maryland, USA
    Isr J Psychiatry Relat Sci 42:51-60. 2005
    ..Because certain side effects may be associated with nonadherence with treatment, more detailed data for each of the SGA with regards to EPS, weight gain and metabolic abnormalities and sexual dysfunction are presented...
  46. pmc Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers
    Kenneth H Levin
    Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD 21224, USA
    Drug Alcohol Depend 111:120-7. 2010
    ..Cannabis withdrawal is not recognized in DSM-IV because of doubts about its clinical significance...
  47. ncbi request reprint Evaluating sexual function in patients with treatment-resistant schizophrenia
    Deanna L Kelly
    Schizophr Res 63:195-6. 2003
  48. ncbi request reprint Olanzapine and risperidone
    Raymond C Love
    Am J Health Syst Pharm 60:487-8; author reply 488-9. 2003
  49. ncbi request reprint Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study
    Do Un Jung
    Department of Psychiatry, Dongseo Hospital, Masan, Republic of Korea
    J Clin Psychiatry 67:1391-6. 2006
    ..This study investigates bone mineral density (BMD) and the association between BMD and hormonal changes in Korean patients with schizophrenia...
  50. ncbi request reprint Fluoxetine augmentation of haloperidol in chronic schizophrenia
    Joo Cheol Shim
    J Clin Psychopharmacol 23:520-2. 2003
  51. ncbi request reprint The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study
    Robert R Conley
    J Clin Psychopharmacol 23:668-71. 2003
  52. ncbi request reprint Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine
    Deanna L Kelly
    J Clin Psychiatry 64:1133-4. 2003
  53. ncbi request reprint The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia
    Do Un Jung
    J Clin Psychopharmacol 25:613-5. 2005
  54. ncbi request reprint Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis
    Joo Cheol Shim
    J Clin Psychopharmacol 27:400-1. 2007
  55. ncbi request reprint Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia
    Joo Cheol Shim
    Department of Psychiatry, Inje University, Busan, Korea
    J Neuropsychiatry Clin Neurosci 17:221-6. 2005
    ..This finding suggests that decreased dopamine (D(2)) receptor sensitivity may result in lower risk of developing TD and may lead to a fuller understanding of the variable expression of D(2)-receptor mediated side effects...
  56. ncbi request reprint Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial
    Joo Cheol Shim
    Clinical Trial Center, Department of Psychiatry and Clinical Pharmacology, Busan Paik Hospital, Inje University, Busan 614 735, Republic of Korea
    Am J Psychiatry 164:1404-10. 2007
    ..The authors investigated the effect of adjunctive treatment with aripiprazole on hyperprolactinemia and psychopathology in patients with schizophrenia maintained with haloperidol...
  57. pmc Quetiapine at high doses for the treatment of refractory schizophrenia
    Douglas L Boggs
    Schizophr Res 101:347-8. 2008
  58. ncbi request reprint Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis
    Tim Lambert
    J Clin Psychopharmacol 24:91-3. 2004
  59. ncbi request reprint Deaths from diabetic ketoacidosis after long-term clozapine treatment
    Heidi J Wehring
    Am J Psychiatry 160:2241-2. 2003
  60. doi request reprint Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report
    Joo Cheol Shim
    J Clin Psychopharmacol 28:353-4. 2008
  61. ncbi request reprint Cortisol response to buspirone in extended abstinent alcoholics
    Young Hoon Kim
    Department of Psychiatry, Busan Paik Hospital 633 165 Gaegum Dong, Busanjin Gu, 614 735, Republic of Korea
    Alcohol Alcohol 39:287-9. 2004
    ..Our results show that cortisol response to buspirone was significantly decreased in alcoholic patients compared to normal controls, reflecting decreased 5-HT1A receptor sensitivity...

Research Grants3

  1. Cardiac-Related Mortality with Atypical Antipsychotics
    DEANNA KELLY; Fiscal Year: 2005
    ..This study is important as data on long-term health outcomes with atypical antipsychotics is lacking from the literature. ..
  2. Comorbid Substance Abuse and Long-Term Health Outcomes in Schizophrenia
    DEANNA KELLY; Fiscal Year: 2007
    ..This will be an important step for improving the lives of people with schizophrenia. ..